Shaw, Emily S;
Stoker, Neil G;
Potter, Jessica L;
Claassen, Helgard;
Leslie, Alasdair;
Tweed, Conor;
Chiang, Chen-Yuan;
... Lipman, Marc; + view all
(2024)
Bedaquiline: what might the future hold?
Lancet Microbe
, 5
(12)
, Article 100909. 10.1016/S2666-5247(24)00149-6.
Preview |
Text
Lipman_1-s2.0-S2666524724001496-main.pdf Download (237kB) | Preview |
Abstract
Tuberculosis drug development has stagnated for decades, so the recent availability of bedaquiline is welcome. Bedaquiline-containing regimens, now the first-line therapy recommended by WHO, have transformed the treatment of drug-resistant tuberculosis, offering safer and more effective oral treatment options. However, key obstacles need to be overcome to ensure global access and prevent the rapid development of resistance against this promising class of drugs. In this Personal View, building on an international workshop held in 2023, we evaluate the current evidence and suggest possible ways forward, recognising the tension between increasing use and slowing the rise of resistance. We also discuss problems in accessing bedaquiline-containing regimens, the potential widening of their use beyond drug-resistant tuberculosis, and lessons for utilising new drugs as they are developed.
| Type: | Article |
|---|---|
| Title: | Bedaquiline: what might the future hold? |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/S2666-5247(24)00149-6 |
| Publisher version: | https://doi.org/10.1016/s2666-5247(24)00149-6 |
| Language: | English |
| Additional information: | This work is licensed under a Creative Commons License. The images or other third-party material in this article are included in the Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc/4.0/ |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Infectious Diseases, Microbiology, DRUG-RESISTANT TUBERCULOSIS, MULTIDRUG-RESISTANT, MYCOBACTERIUM-TUBERCULOSIS, ATP SYNTHASE, CLOFAZIMINE, PATIENT, PYRAZINAMIDE, EMERGENCE, RIFAMPIN, AFRICA |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Respiratory Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10209600 |
Archive Staff Only
 |
View Item |
